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ABSTRACT 21 
The rodent pancreatic AR42J-B13 (B-13) cell line differentiates into non-replicative hepatocyte-like 22 
cells in response to glucocorticoid mediated via the glucocorticoid receptor (GR).  The aims of this 23 
study were to identify a human cell line that responds similarly and investigate the mechanisms 24 
underpinning any alteration in differentiation.  Exposing the human pancreatic adenocarcinoma 25 
(HPAC) cell line to 1 - 10µM concentrations of dexamethasone (DEX) resulted an inhibition of 26 
proliferation, suppressed carcinoembryonic antigen expression, limited expression of pancreatic acinar 27 
and hepatic gene expression and significant induction of the constitutively-expressed hepatic CYP3A5 28 
mRNA transcript.  These changes were associated with a pulse of genomic DNA methylation and 29 
suppressed notch signalling activity.  HPAC cells expressed high levels of GR transcript in contrast to 30 
other nuclear receptors - such as the glucocorticoid-activated pregnane X receptor (PXR) - and GR 31 
transcriptional function was activated by DEX in HPAC cells.  Expression of selected hepatocyte 32 
transcripts in response to DEX was blocked by co-treatment with the GR antagonist RU486.  These 33 
data indicate that the HPAC response to glucocorticoid exposure includes an inhibition in proliferation, 34 
alterations in notch signaling and a limited change in the expression of genes associated with an acinar 35 
and hepatic phenotype.  This is the first demonstration of a human cell responding to similarly to the 36 
rodent B-13 cell regarding formation of hepatocyte-like cells in response to glucocorticoid.  Identifying 37 
and modulating the ablating factor(s) may enhance the hepatocyte-like forming capacity of HPAC cells 38 
after exposure to glucocorticoid and generate an unlimited in vitro supply of human hepatocytes for 39 
toxicology studies and a variety of clinical applications. 40 
41 
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1. Introduction 42 
The pancreas and liver are embryonic endoderm-derived tissues with a close developmental 43 
relationship (in that hepatocytes and biliary epithelial cells are derived from a population of embryonic 44 
pancreas cells (Deutsch et al., 2001)).  Both pancreas and liver tissues have endocrine and exocrine 45 
functions with ductal progenitor cells in each tissue generating the endocrine (e.g. islet cells in 46 
pancreas) and exocrine (i.e. acinar cells in pancreas) tissue.  Hepatocytes in the liver perform both 47 
endocrine (e.g. albumin secretion) and exocrine (bile acid excretion) functions (Wallace et al., 2008). 48 
At present, limited supplies of human liver, the costs of hepatocyte isolation and difficulties in 49 
maintenance of function in vitro limit use of hepatocytes in cell-based studies (Wallace et al., 2010a).  50 
Considerable effort has been directed towards generating hepatocytes from either embryonic stem cells 51 
or induced pluripotent stem cells (Sullivan et al., 2010; Rashid et al., 2010; Hannan et al., 2013).  52 
Improvements in protocols have increased the proportion of cells differentiating toward hepatocytes but 53 
there remain a number of key hurdles to overcome before they will have significant basic or clinical 54 
utility.  These include a lack of maturity, such that the cells remain at best, functionally equivalent to 55 
foetal hepatocytes and that they de-differentiate in vitro from a difficult-to-predict peak in function.  56 
There is also currently a requirement to follow complex differentiation protocols and the high costs 57 
associated with their production limit uptake and use (Wallace et al., 2010a; Szkolnicka et al., 2013). 58 
An expandable rat pancreatic exocrine-like and/or ductal progenitor cell line - AR42J-B13 59 
(henceforth referred to as B-13 cells) – to our knowledge, is unique in its quantitative ability to 60 
differentiate into hepatocyte-like cells that remain stably differentiated for many weeks on simple 61 
culture substrata.  B-13 cells differentiate into non-replicative functional hepatocyte-like (B-13/H) cells 62 
after exposure to a single simple hormone (glucocorticoid), with many functions at levels quantitatively 63 
similar to the levels in freshly isolated rat hepatocytes (Shen et al., 2000; Marek et al., 2003; Wallace et 64 
al., 2010a; Probert et al., 2015).    65 
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 It is known that pathological conditions lead to the appearance of hepatocyte-like cells in the 66 
pancreas (Zaret et al., 2008).  For an extensive review of rodent and human data with regard to this 67 
issue, see Probert et al (2015).  Since the proliferation of human pancreatic adenocarcinoma (HPAC) 68 
cells is inhibited after exposure to glucocorticoid (Gower et al., 1994; Norman et al., 1994), we 69 
hypothesised that this cell line could form the basis of a human equivalent to the B-13 cell, capable of 70 
conversion into functional hepatocyte-like cells.  This paper demonstrates for the first time, that 71 
glucocorticoid exposure and the inhibition in proliferation, is also associated with alterations in notch 72 
signaling and a change in the expression of genes associated with acinar and hepatic phenotypes.   73 
74 
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 75 
2. Results 76 
Glucocorticoid exposure inhibits HPAC proliferation and promotes an epithelial phenotype in 77 
HPAC cells. 78 
Supplementary Fig 1A demonstrates that exposing HPAC cells to DEX resulted in a dose-79 
dependent reduction in nuclear proliferating cell nuclear antigen (PCNA) expression within 2 days of 80 
exposure and an inhibition in proliferation (Supplementary Fig 1B) - as previously reported (Gower et 81 
al., 1994; Norman et al., 1994) - with a 50% inhibitory concentration between 1 - 10µM.  DEX 82 
exposure also resulted in a morphological change to a more epithelial phenotype (Supplementary Fig. 83 
1B) and to a reduction - or complete loss in most cells - in expression of the carcinoembryonic antigen 84 
(CEA) (Supplementary Fig. 1C).   A similar effect was also seen with the ductal marker cytokeratin 19 85 
(Supplementary Fig. 1D). 86 
 87 
Glucocorticoid exposure induces a limited expression of hepatocyte transcripts in HPAC cells. 88 
Fig 1A demonstrates that HPAC expressed undetectable levels of the hepatocyte transcripts 89 
CYP2E1 and albumin whereas after treatment with DEX, these transcripts became detectable as 90 
determined by semi-quantitative RT-PCR after 7 or 14 days respectively.  These data were confirmed 91 
by quantitative RT-PCR based on 7 separate assessments over a period of several months (Fig 1B).  Fig 92 
1B indicates that CYP2E1 and albumin transcripts were increased to low levels relative to human 93 
hepatocytes (approx. 100 fold lower) although responses between cultures were subject to great 94 
variability.  It has been reported that HPAC cells express CYP3A5 based on Western blotting of cell 95 
extracts and metabolism of midazolam to 1′-hydroxymidazolam in cultured cells, although no 96 
comparison was made to human hepatocytes (Schmiedlin-Ren et al., 2001).  Figure 1B supports the 97 
observation that CYP3A5 is constitutively expressed in HPAC cells and has the potential for activity 98 
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since HPAC cells also constitutively expressed hepatocyte levels of the P450 reductase (POR) 99 
transcript.  Fig 1B also indicates that DEX treatment resulted in a statistically significant 2.6 fold 100 
increase in CYP3A5 mRNA transcript expression.  In contrast, the major hepatocyte expressed 101 
CYP3A4 transcript showed a mean fall in expression after DEX treatment.  In terms of liver-enriched 102 
transcription factor gene expression, Fig 1B indicates that there was a significant 4.8 fold increase in 103 
CEBPβ transcript expression after DEX treatment whereas the both HNF1α and HNF4α expressions 104 
were suppressed.  Given that HPAC constitutive CEBPβ expression was in the range seen in human 105 
hepatocytes, this suggests CEBPβ induction is a candidate driver for some of the changes seen in 106 
response to DEX.  Fig. 1C demonstrates however, that expression of CYP2E1 and albumin proteins 107 
were low to undetectable in HPAC cells after treatment with DEX and this was confirmed on 108 
examination of cytochrome P450 enzyme activities, including after exposure to a cocktail of 109 
compounds that induce these enzymes (Fig. 1D). 110 
 111 
The mechanism of acinar and hepatocyte-like formation in HPAC cells is associated with a pulse in 112 
DNA methylation and a suppression of Notch signalling. 113 
Previous work has shown that glucocorticoids bind to the glucocorticoid receptor (GR) in B-13 114 
cells, resulting in an induction of serine/threonine-protein kinase - also known as serum and 115 
glucocorticoid-regulated kinase 1 (Sgk1) - expression (Wallace et al., 2011).  This is followed by a 116 
pulse in genomic DNA methylation (Fairhall et al., 2016), phosphorylation of β-catenin leading to 117 
transient down-regulation in canonical wnt signaling (Wallace et al., 2010b) and increases in the 118 
expression of a variety of transcription factors associated with hepatocyte phenotype such as Cebp-β 119 
(Shen etv al., 2000; Fairhall et al., 2016), Cebp-α, Hnf1α and Hnf4α (Fairhall et al., 2016). 120 
Fig 2A demonstrates that exposing HPAC cells to DEX resulted in a rapid pulse in genomic 121 
DNA methylation as observed to occur in B-13 cells (Fairhall et al., 2016).  DEX treatment in the 122 
hepatocellular carcinoma HepG2 cell line resulted in a demethylation.     In contrast to B-13 cells 123 
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however, the wnt signalling pathway was inactive in HPAC cells (Fig. 2B) and there was no induction 124 
of SGK1 after DEX treatment (data not included).  Rather, HPAC cells expressed a functional DEX-125 
suppressed notch signalling pathway which was absent in B-13 cells (Fig.2C and Fig. 2D).  Recent 126 
work in the liver has demonstrated that notch ligand (Jagged 1) from hepatic portal (myo)fibroblasts 127 
activates notch signalling and promotes murine hepatic bi-progenitor (oval cell) differentiation into 128 
cholangiocytes and that Wnt3a from macrophages promotes hepatocyte formation (Boulter et al., 129 
2012).  In order to test whether (myo)fibroblasts inhibit hepatic trans-differentiation of HPAC cells to 130 
hepatocyte-like cells, mouse liver (myo)fibroblasts were co-cultured with HPAC cells.  Co-culture 131 
inhibited the induction of hepatocyte mRNA transcripts in response to DEX (Fig 2E).   132 
 133 
 134 
HPAC conversion to an hepatocyte-like phenotype is dependent on the GR. 135 
 Fig. 3A demonstrates that HPAC cells expressed relatively high levels of GR in contrast to 136 
undetectable levels of several nuclear receptor mRNA transcripts (that share overlapping ligand 137 
binding characteristics with the GR), as determined by RT-PCR.  Expression of GR mRNA (using 138 
primers that hybridize to all transcripts) increased (Fig. 3A) and the levels of the dominant-negative 139 
(Lewis-Tuffin et al., 2006) truncated variant GRβ mRNA decreased (Fig. 3B) in HPAC cells after 140 
treatment with DEX suggesting the potential for a positive feedback for promoting glucocorticoid 141 
responsiveness (as observed in B-13 cells (Fairhall et al., 2016)).  However, relatively high (~ 10-6 – 142 
10-5M) concentrations of DEX, typically necessary for activation of the human pregnane X receptor 143 
(PXR) (Harvey et al., 2000), were required to promote hepatic changes in HPAC cells.  In contrast, B-144 
13 cells respond to DEX in the ~10-8 M range (Shen et al., 2000; Marek et al., 2003; Probert et al., 145 
2015), expected given the kD of DEX for the GR is ~10
-9M (Wright and Paine, 1994).  DEX maximally 146 
activated the GR at ~ 10-6 M in HPAC cells based on transfection of a synthetic GR-responsive reporter 147 
gene construct, an effect inhibited by the GR antagonist RU486 (Fig. 3C).  Induction of hepatocyte 148 
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transcript expression by DEX was also inhibited by co-treatment with RU486 (Fig. 3D) and human 149 
PXR activators [phenobarbitone, rifampicin and metyrapone (Goodwin et al., 2001; Harvey et al., 150 
2000) failed to induce hepatocyte transcript expression (Fig. 3E) or PXR-dependent reporter gene 151 
induction (Fig. 3F) in HPAC cells.  These data therefore support the central role of the GR in mediating 152 
the induction of an acinar and hepatocyte-like phenotype by DEX in HPAC cells. 153 
 Since several glucocorticoid resistance phenotypes have been documented to be associated with 154 
polymorphisms in the human GR gene (Charmandari et al., 2013), the full amino acid sequence-155 
encoding HPAC GR cDNA sequence [encompassing 2395bp containing the coding sequence of the 156 
predominant human variant 1 transcript, also known as GRα or GR-A; note, that 5 other variant 157 
transcripts encode the same protein isoform] was cloned by RT-PCR from HPAC mRNA using 158 
overlapping amplicons (see Fig. 4A and supplementary Fig. 2) and sequenced.  The entire amino acid 159 
coding sequence of the HPAC GR cDNA sequence was identical to the human variant 1 transcript (see 160 
supplementary data 2) except for a synonymous mutation in the C terminus of the protein - AAT to 161 
AAC (Fig. 4B). 162 
 A 3 nucleotide (GTA) insertion that predicts an insertion of an arginine amino acid at position 163 
452 in the DNA binding domain of the HPAC GR protein was also detected (Fig 4C).  This latter 164 
change has been previously reported to occur through alternative splicing whereupon 3 bases are 165 
retained from the intron separating exons 3 and 4, leading to an identical variant transcript and an 166 
insertion of an arginine (Rivers et al., 1999).  Since the HPAC GR US2/DS2 PCR product sequence 167 
results in the presence of a single AccI restriction endonuclease site not present in the wild type 168 
transcript (Fig. 4D), RFLP was employed to estimate the proportion of HPAC GR variant transcripts 169 
encoding a GR protein containing an additional arginine in the DNA binding domain. Fig. 4E 170 
demonstrates that variant transcript encoding an insertion of an arginine amino acid at position 452 171 
formed a minor proportion of the total GR transcripts present, a phenomenon also noted in normal 172 
human tissues (Rivers et al., 1999). 173 
 9 
174 
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3. Discussion 175 
 Generating good quality, functional human hepatocytes that can be used as an effective tool to 176 
study human hepatic biology and model typical responses to drugs and chemicals remains a significant 177 
challenge in Hepatology and Toxicology.  Limited access to normal human liver tissue and 178 
functionality and cost issues with stem cell-derived hepatocyte-like cells preclude their widespread 179 
utility and applicability.  Given that a rodent pancreatic progenitor-like B-13 cell line with acinar 180 
properties is capable of generating hepatocyte-like cells (Wallace et al., 2010a; Shen et al., 2000; 181 
Marek et al., 2003; Wallace et al., 2010b; Wallace et al, 2011; Probert et al., 2014; Probert et al., 2015; 182 
Probert et al., 2016; Fairhall et al., 2016), manipulation of a similar human cell may offer the prospect 183 
of an unlimited supply of functional human hepatocytes.   184 
 Previous recent work has confirmed that the rodent exocrine pancreatic response to elevated 185 
glucocorticoid of hepatic differentiation (Wallace et al., 2009; Wallace et al., 2010c) is also observed in 186 
man (Fairhall et al., 2013a).  A human pancreatic ductal-like cell line that showed a similar behaviour 187 
to B-13 cells was therefore sought and HPAC cells were identified.  As observed with B-13 cells 188 
Fairhall et al., 2013b), although it is considered to be a cancer ductal-like cell line, HPACs 189 
demonstrated the property of being unable to proliferate in soft agar (data not included).  HPAC cells 190 
also shared a number of qualitative properties associated with B-13 cells, including high expression of 191 
the GR and a functional response to glucocorticoids (i.e. transcriptional effects).  In addition, after 192 
exposure to glucocorticoid, both HPAC and B-13 cells undergo a robust pulse in genomic DNA 193 
methylation; an induction of selected hepatocyte transcripts (albumin, CYP2E1); a decrease in 194 
proliferation and an alteration in morphology (Fairhall et al., 2016).  In all cases where it has been 195 
investigated, these effects were inhibited by GR antagonists such as RU486, supporting a pivotal role 196 
for the GR in mediating these responses. 197 
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 It remains the case however, that there are differences between the mechanism(s) regulating B-198 
13 and HPAC cell responses to glucocorticoid exposure.  Glucocorticoid exposure in HPACs resulted 199 
in a quantitatively markedly reduced level of hepatocyte mRNA transcript and protein expression 200 
levels than that seen in hepatocyte-like B-13/H cells (which are similar in many cases to rat liver levels 201 
(Fairhall et al., 2016)).  In addition, for HPAC cells, SGK1 induction did not occur (data not included); 202 
higher concentrations of DEX were required; Wnt signalling was not active and the presence of 203 
myofibroblasts inhibited hepatic transcript expression (with a more pronounced effect on CYP2E1 than 204 
albumin transcript expression), whereas they promote hepatocyte-like B-13/H formation (Fairhall et al., 205 
2014).   A possible reason why albumin escaped a robust block in expression in the presence of co-206 
cultured myofibroblasts may be due divergent regulation of these 2 genes, with CYP2E1 expression 207 
being directly regulated by the Wnt signalling pathway (Braeuning et al., 2009; Gerbal-Chaloin et al., 208 
2014), whereas no such direct regulatory role has been defined for the albumin gene. 209 
 With respect to higher concentrations of DEX being required for conversion to hepatocyte-like 210 
cells compared to B-13 cells, this is unlikely to be due to HPAC GR variant expression, since the only 211 
variant GR transcript identified was present at similar levels (between 3.8 and 8.7% of total GR) in 212 
normal tissues (Rivers et al., 1999). Several glucocorticoid resistance phenotypes have been 213 
documented to be associated with polymorphisms in the human GR gene (Charmandari et al., 2013).  214 
However, sequencing and RFLP analysis reported herein suggest that a polymorphic variant is not 215 
expressed in HPAC cells and the gene encoding the protein is intact and identical to the human w/t GR.  216 
Furthermore, Scatchard analysis of dexamethasone binding data in HPAC extracts identified a single 217 
class of high-affinity binding sites with a kD of 3.8 ± 0.9 nM and maximum binding site concentration 218 
of 523 ± 128 fmol/mg protein (Gower et al., 1994) suggestive of normal GR - glucocorticoid ligand 219 
interaction.  A more likely scenario is that the GR transcriptional response is ablated by a non-GR 220 
factor(s).  Identifying and modulating the ablating factor(s) may enhance the hepatocyte-like forming 221 
capacity of HPAC cells after exposure to glucocorticoid. 222 
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 Despite clear qualitative similarities to B-13 cells, HPAC cells expressed low levels of 223 
hepatocyte transcripts after treatment with glucocorticoid.  Therefore, on this basis, although of 224 
mechanistic interest, they are of limited practical value at present.  However, given their ease and 225 
simplicity of propagation, genetic manipulation of HPAC cells though GR-dependent induction of 226 
appropriate factors (e.g. liver specific transcription factors) will likely amplify the hepatic phenotype.  227 
The HPAC cell line may therefore be a base from which to generate an unlimited supply of donor free 228 
human hepatocyte-like cells. 229 
 230 
 231 
4. Materials and Methods 232 
 233 
4.1 Materials. 234 
 HPAC (ATCC® CRL-2119™) cells were originally purchased from LGC Standards 235 
(Middlesex, UK).  HPAC cells used in these studies were confirmed to be of human female origin  236 
(data not included) based PCR-RLFP analysis of the mitochondrial genome-encoded cytochrome b 237 
according to Losi et al. (2008) using primers L14816 and H15173 for species determination and female 238 
using primer sequences given in supplementary data 3.  The renilla reporter vector RL-TK was 239 
originally purchased from Promega (Southampton, UK).  The Notch reporter constructs pCBFRE-luc 240 
and pCBFRE-(mut)-luc as described (Yu et al., 2008) were obtained from Addgene.  Wnt signalling 241 
reporter constructs “Topflash” and “Fopflash” were also obtained from Addgene and used as 242 
previously described (Wallace et al., 2010b).  All other plasmids and their construction have been 243 
previously described - GRE4-pGL4.28 (Fairhall et al., 2016); (ER6)3-pGL3promoter (Haughton et al., 244 
2006).  Pancreas tissue was originally obtained with patient consent through the Newcastle 245 
Hepatopancreatobiliary Research Tissue Bank, with ethical approval by the Newcastle & North 246 
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Tyneside 2 Research Ethics Committee.  Pancreas tissue was taken from the margins of fresh tissue 247 
removed from donors due to the presence of tumours, but was histologically normal.  Human acinar 248 
cells were prepared as previously outlined (Fairhall et al., 2013a).  Human hepatocytes were isolated 249 
from a 42 year old male donor by collagenase perfusion essentially as previously described (Harvey et 250 
al., 2000).  Cells were washed in ice-cooled PBS and cell pellet aliquots snap frozen in liquid nitrogen 251 
prior to long term storage at -80oC for later use in assays.  Human liver tissue for hepatocyte isolation 252 
was ethically obtained via the Newcastle Biobank (https://www.ncl.ac.uk/biobanks/) with over-arching 253 
ethical approval from the Newcastle & North Tyneside 1 Research Ethics Committee. 254 
 255 
4.2 Cell culture 256 
 All cell lines were routinely cultured in low glucose (1g/L) Dulbecco’s Modified Eagle’s 257 
Medium (DMEM) containing 10% (v/v) fetal calf serum (FCS), 100units/ml penicillin, 100μg/ml 258 
streptomycin and 0.584g/L L-glutamine in an humidified incubator at 37oC and an atmosphere of 5% 259 
CO2 in air.  Cells were treated with dexamethasone (DEX) through addition of 1000-fold molar ethanol 260 
solvated stocks, with controls treated with 0.1% (v/v) ethanol vehicle as control.  HPACs were exposed 261 
to a multiple of 4 chemicals in an attempt to induce expression of several hepatic 1-4 sub-families of 262 
cytochromes P450 (CYP): 20µM β-naphthoflavone, 1mM sodium phenobarbitone, 20µM rifampicin 263 
and 100µM bezafibrate, primarily inducing hepatocyte CYP1A (Harvey et al., 2000), CYP2B (Pascussi  264 
et al., 2000), CYP3A (Wright, 1999) and CYP4A (Alvergnas et al. 2009) sub-families respectively.  265 
Cells were treated daily for 4 days and harvested 24 hours after the last treatment on day 5.  Liver 266 
myofibroblasts were prepared through isolation of quiescent hepatic stellate cells from adult male 267 
C57Bl/6 mice and activation to myofibroblasts through culture on plastic in high glucose (5g/L) 268 
DMEM supplemented with 20% FCS, 100units/ml penicillin, 100μg/ml streptomycin, 50µg/ml 269 
gentamycin and 0.584g/L L-glutamine as previously described (Ebrahimkhani et al., 2011) prior to 270 
culture in medium used for HPAC cells and co-culture experiments.  Photomicrographs of 5 randomly 271 
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selected fields of view were taken per time point and treatment and cell number determined be an 272 
operator blinded to the treatments.  The mean cell number from at least 3 separate culture per treatment 273 
were used to determine the mean and SD cell number for each time point.  For soft agar cultures, cells 274 
were sub-cultured and suspended at 2.5 × 103 cells/mL in media containing 0.35% (w/v) agarose as 275 
previously outlined (Fairhall et al., 2013b).  Cells were cultured for 2 weeks, before staining each well 276 
with 500 μl of 0.005% (w/v) crystal violet for 1 hour to visualize cells. 277 
 278 
4.3 Gene expression studies 279 
 DNA, total RNA and protein extracts were prepared and RT-PCR and PCR were performed as 280 
outlined (Ebrahimkhani et al., 2011; Wallace et al., 2010c) using primers provided in supplementary 281 
data 3.  qRT-PCR was performed using validated Taqman primers supplied by Applied Biosystems.  282 
Western blotting, immunocytochemistry and immunohistochemistry were performed as described 283 
(Ebrahimkhani et al., 2011; Wallace et al., 2010c).  Cytochrome P450 CYP2E activities were 284 
determined using para-nitrophenol as previously described (Marek et al., 2005).  CYP3A4 activities 285 
were determined as described (Probert et al., 2014) using a kit supplied by Promega.  286 
 287 
4.4 Genomic DNA methylation 288 
 Genomic DNA was isolated as outlined (Fairhall et al., 2016) and total global methylation 289 
determined using a Sigma Imprint® Methylated DNA quantification kit, essentially according to the 290 
manufacturer’s instructions.  Typically, 100ng of DNA from each treatment was analysed and 291 
compared to standard methylated DNA provide in the kit. Relative global methylation levels were 292 
calculated as percentage compared to the fully methylated control. 293 
 294 
4.5 Transfection and Dual-Luc reporter gene assays 295 
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 HPAC cells were transfected with PEI reagent (MerckMillipore, Nottingham, UK); HepG2 296 
cells and B-13 cells were transfected with Genejuice (Merck, Nottingham, England) according to the 297 
manufacturer’s instructions.  For luciferase-based reporter gene studies, luciferase and renilla activities 298 
in cell extracts were assayed using the Dual-Luciferase assay system from Promega (Southampton, 299 
UK) using a luminometer.  Renilla activities were used at all times to normalise for transfection 300 
efficiencies. 301 
 302 
4.6 Sequence determination of the HPAC GR cDNA sequence 303 
 RNA was isolated from HPAC cells (and human hepatocytes as positive control) and first 304 
strand cDNA synthesised using MMLV (using a kit supplied purchased from Sigma, Pool, UK) primed 305 
using random hexamers (Promega, Southampton, UK). Sections of the full amino acid sequence-306 
encoding GR [encompassing 2395bp containing the coding sequence of the predominant human variant 307 
1 transcript, also known as GR-alpha or GR-A; note, that 5 other variant transcripts encode the same 308 
protein isoform] was then amplified by PCR using a proof reading polymerase - Phusion® high fidelity 309 
kit with GC buffer (NEB, Hitchin, UK) using primer pairs and the conditions as outlined in 310 
supplementary data 2.  PCR products were blunt end TOPO cloned (Invitrogen) and EcoR1 restricted to 311 
confirm PCR product insertion.  Selected clones were then sequenced 6 times in total (3 times in either 312 
direction) and the relevant (non-primer derived) GR encoding sequences aligned using Omega Clustal 313 
(http://www.ebi.ac.uk/Tools/msa/clustalo/).  In all cases, the sequences were 100% identical.  314 
Restriction of pUC19 (Invitrogen) or PCR products with AccI (Thermo Scientific) was performed at 315 
37oC overnight following the manufacturer’s instructions. 316 
317 
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Summary statement 330 
 Glucocorticoid exposure suppresses HPAC cell proliferation and induces an hepatocyte-like 331 
phenotype. 332 
 Change in differentiation is dependent on the glucocorticoid receptor, not other nuclear 333 
receptors (e.g. PXR). 334 
 Differentiation change is associated with a pulse in genomic DNA methylation and suppression 335 
of the notch signalling pathway. 336 
337 
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Figure legends 452 
 453 
Figure 1.  Effect of DEX exposure on the expression of hepatocyte transcripts, proteins and activities 454 
in HPAC cells.  A, RT-PCR for the indicated transcripts in HPAC cells, results typical of 7 separate 455 
experiments.  B, qRT-PCR analysis for the expression of the indicated transcripts in RNA isolated from 456 
either HPAC cells treated with 10µM DEX for 14 days or human liver, expressed relative to their 457 
levels in HPAC cells (set equal to 1).   Data are the mean of 3 separate determinations from RNA 458 
pooled from 3 human livers and 7 separate HPAC experiments. C, Western blot for the indicated 459 
protein, data typical of 6 separate determinations.  D, Cytochrome P450-dependent enzyme activities in 460 
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HPAC cells treated as indicated.  Data are the mean and standard deviation of 3 separate HPAC 461 
experiments or 3 separate human hepatocyte preparations.  D, CYP2E and CYP3A4 enzyme activities 462 
in HPAC cells.  HPAC cells were treated 10µM DEX for 14 days (DEX), and for the last 5 days with a 463 
cocktail of cytochrome P450 inducers (IND) before isolation of cells and assays.  Activities are 464 
normalized to protein, expressed relative to human hepatocytes (Human heps, mean and SD of 3 465 
determination from the same donor cells) and are the mean and SD of 3 separate experiments. 466 
 467 
Figure 2.  HPAC conversion to an hepatocyte-like phenotype is associated with a pulse in DNA 468 
methylation and a suppression of Notch signalling.  A, genomic DNA methylation in the indicated 469 
cell type in response to DEX treatment or vehicle control (0.1% ethanol), data are the mean and SD of 470 
3 separate determinations from the same experiment, typical of at least 3 separate experiments.  471 
*significantly different from equivalent vehicle control treated cells treated for the same period of time 472 
using the Student’s T test (two tailed), P > 0.95.   B, Wnt signalling as determined in cells transfected 473 
with 2 µg Topflash (T) or Fopflash (F) luciferase reporter constructs and 0.2 µg RL-TK as outlined in 474 
methods section followed by a determination of luciferase and renilla activities 24 hours later.  Results 475 
are the mean and SD of 3 separate determinations from the same experiment, typical of 3 separate 476 
experiments. C, Notch signalling in cells transfected with 2 µg pCBFRE or pCBFREmut luciferase 477 
reporter constructs and 0.2 µg RL-TK as outlined in methods section followed by a determination of 478 
luciferase and renilla activities 24 hours later or after a further 24 hours treatment with DEX.  Results 479 
are the mean and SD of 3 separate determinations from the same experiment, typical of 3 separate 480 
experiments.  Significantly different from *mutant or #DEX-treated cells using the Student’s T test 481 
(two tailed), P > 0.95.  D, RT-PCR for the expression of notch ligand and receptor mRNA transcripts in 482 
HPAC cells and comparison to other human tissues.  E, HPAC cells were co-cultured where indicated 483 
with culture-activated mouse liver myofibroblasts and treated with DEX or vehicle control for 14 days 484 
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prior to analysis for the indicated transcript.  α-Smooth muscle actin (α-sma) is a transcript marker 485 
expressed in liver myofibroblasts (Wallace et al., 2008). 486 
 487 
Figure 3.  Glucocorticoid-dependent hepatocyte-like phenotype in HPAC cells is mediated via the 488 
glucocorticoid receptor.  A, RT-PCR for the expression of selected nuclear receptor mRNA transcripts 489 
in HPAC cells and comparison to other human tissues, data are typical of at least 3 separate 490 
determinations. B, RT-PCR for the expression of GR (also termed GRα) and the dominant-negative 491 
GRβ mRNA transcripts in HPAC cells and comparison to other human tissues.  The GRβ protein is 492 
generated from an alternate mRNA transcript from the GR gene. C, HPAC cells were transfected with 493 
2 µg GRE4-pGL4.28 and 0.2 µg RL-TK as outlined in methods section and after 24 hours, treated with 494 
the indicated concentration of DEX and/or 10µM RU486 prior to determination of luciferase and 495 
renilla activities 24 hours later.  Results are the mean and SD of 3 separate determinations from the 496 
same experiment, typical of 3 separate experiments.  Significantly different from *RU486-treated or 497 
$untreated cells using the Student’s T test (two tailed), P > 0.95.  D, Effect of RU486 on DEX-498 
dependent hepatocyte mRNA transcript expression.  Cells were treated for 14 days with the indicated 499 
concentration of DEX and/or RU486 prior to RT-PCR analysis for the indicated transcripts, results 500 
typical of 3 separate experiments; E, Effect of PXR activators (i.e. DEX at the concentration employed, 501 
phenobarbitone (PB), rifampicin (RIF) and metyrapone (MET) – see Harvey et al., 2000)) treatment on 502 
hepatocyte marker gene expression in HPACs.  HPACs were treated as indicated prior to RT-PCR 503 
analysis for the indicated transcripts, results typical of 3 separate experiments. F, HPAC cells were 504 
transfected with 2 µg ER6-pGL3promoter and 0.2 µg RL-TK as outlined in methods section and after 505 
24 hours, treated with DMSO vehicle control (0.1% v/v) or the indicated concentration of DEX or RIF 506 
prior to determination of luciferase and renilla activities 24 hours later.  Results are the mean and SD of 507 
3 separate determinations from the same experiment, typical of 3 separate experiments.  *Significantly 508 
different from DMSO vehicle treated cells using the Student’s T test (two tailed), P > 0.95. 509 
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 510 
Figure 4.  Overlapping RT-PCR amplification and sequencing of the HPAC GR.  A, schematic 511 
diagram of the human GR gene and strategy employed to amplify regions using HPAC RNA or human 512 
liver RNA as template, lower panels PCR products subsequently cloned and sequenced.  B, sequence 513 
data demonstrating synonymous mutation in the 3’ terminus of the HPAC cDNA sequence compared to 514 
the wild type (w/t) sequence.  C, sequence data demonstrating 3 nucleotide (GTA) insertion predicting 515 
an insertion of an arginine amino acid at position 452 in the DNA binding domain of the HPAC GR 516 
protein.  D, Identification of an AccI restriction endonuclease site in the US2/DS2 3 nucleotide (GTA) 517 
insertion PCR product, which is absent from the w/t PCR product.  E, AccI restriction, left panel of 518 
pUC19 plasmid DNA which contains a single AccI restriction site leading to linearization of the 519 
plasmid (rp); right panel, restriction of US2/DS2 PCR product derived from HPAC RNA, with 520 
restriction giving w/t and a fragment of DNA only generated from PCR product amplified from the 521 
variant transcript encoding an insertion of an arginine amino acid at position 452 (variant).  Note, 522 
restriction of individual pCR plasmid clones from the US2/DS2 PCR product generated similar results 523 
(i.e. minority contained AccI restriction sites), data not included. 524 
525 
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